The Claim
Plasma levels of myeloperoxidase (MPO) are associated with both cross-sectional and longitudinal risk of mild cognitive impairment in older adults aged 70–80 at high risk of mobility disability.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Higher levels of myeloperoxidase in the blood are linked to a greater likelihood of mild cognitive impairment in older adults aged 70–80 who are at high risk of mobility disability, both at a single point in time and over time.
See the scientific wording
Plasma levels of myeloperoxidase (MPO) are associated with both cross-sectional and longitudinal risk of mild cognitive impairment in older adults aged 70–80 at high risk of mobility disability, making it one of the few SASP biomarkers with consistent predictive value across time points, suggesting its potential utility as a biomarker for cognitive aging.
White blood cells release an enzyme that creates harmful chemicals in the blood, which enter the brain and damage brain cells and their connections, leading to memory problems.
What the research says
1 studyThis study found that older adults with higher levels of a blood protein called MPO were more likely to have memory problems now and more likely to develop them in the next two years. This makes MPO a promising sign to watch for brain health in this group.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.